Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
|View printer-friendly version|
|Charles River Laboratories Highlights Commitment to Oncology Research at 2019 AACR Annual Meeting|
Researchers will highlight work in BRCA-deficient and rare pediatric cancers
Charles River’s team of industry-leading oncology
experts have been named as co-inventors on more than 60 patents
secured by clients for compounds with an oncology indication, including
one launched product, and have produced numerous development candidates
in this therapeutic area. Additionally, the Company worked on over 85
percent of all oncology therapies approved by the
Combination Therapies for Breast Cancer
PARP inhibitors have shown promise when used in combination with
immunotherapy in women with breast and ovarian cancers who carry the
BRCA mutations. In an oral presentation at the AACR Annual Meeting,
Collaboration in Pediatric Oncology
Cancer remains the leading cause of death from disease among children, making a continued focus on research in this field extremely important. Charles River has partnered with Meds4Kids Pharma (M4K), an organization using open science to revolutionize how affordable new treatments are discovered and developed.
Since 2017, Charles River has donated drug discovery services to M4K, including medicinal and synthetic chemistry. Working collaboratively with M4K and their open science partners, the team has made progress towards the identification of potent, selective, brain-penetrant ALK2 inhibitors.
At the AACR Annual Meeting,
Additionally, Charles River is a part of the Innovative Therapies for Children with Cancer Paediatric Preclinical Proof-of-Concept Platform (ITCC-P4), a public-private partnership with 21 members focused on establishing 400 new patient-derived xenografts (PDX) of high-risk pediatric tumors. By establishing and characterizing these PDXs, the consortium, funded under IMI2 Grant Agreement No. 116064, aims to build a sustainable, comprehensive platform for more translational drug testing.
Charles River Launches New Drug Discovery Platforms
At the AACR Annual Meeting Charles River is also launching a new model for oncology research. The HuPBMC-NCG Humanized Model is a humanized, PBMC-engrafted NCG mouse. This study-ready model eliminates the time, energy, and resources spent validating and humanizing a model, enabling researchers to quickly initiate short-term in vivo studies.
Humanized mice, which harbor human immune cells, can be utilized to test
the safety and efficacy of compounds that manipulate the immune system
to fight cancer. The HuPBMC-NCG Humanized Model will be commercially
In addition, Distributed Bio scientists will join the Charles River team to highlight their recently announced partnership. A combination of Distributed Bio’s antibody discovery platform and Charles River’s extensive drug development expertise creates an elite end-to-end solution for therapeutic antibody discovery and development. With access to the Distributed Bio’s SuperHuman, AbGenesis, and Tumbler technologies, clients can discover, analyze, and engineer therapeutic antibodies with unprecedented speed.
A full schedule of Charles River’s activities during AACR 2019 is available online. Reprints of each poster will be available in Booth 2914 during the conference, and Charles River experts will be available for meetings to discuss how an integrated approach can support drug discovery and development programs from hit identification to IND (Investigational New Drug) filing.
Throughout the conference, Charles River will be providing live updates on the Eureka Blog, including reviews of scientific sessions and input on the research being presented.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.